RT Journal Article
SR Electronic
T1 Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP 1243
OP 1250
DO 10.1136/thoraxjnl-2021-217976
VO 77
IS 12
A1 Pitre, Tyler
A1 Mah, Jasmine
A1 Helmeczi, Wryan
A1 Khalid, Muhammad Faran
A1 Cui, Sonya
A1 Zhang, Melanie
A1 Husnudinov, Renata
A1 Su, Johnny
A1 Banfield, Laura
A1 Guy, Brent
A1 Coyne, Jade
A1 Scallan, Ciaran
A1 Kolb, Martin RJ
A1 Jones, Aaron
A1 Zeraatkar, Dena
YR 2022
UL http://thorax.bmj.com/content/77/12/1243.abstract
AB Background Idiopathic pulmonary fibrosis (IPF) is a respiratory disorder with a poor prognosis. Our objective is to assess the comparative effectiveness of 22 approved or studied IPF drug treatments.Methods We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and clinicaltrials.gov from inception to 2 April 2021. We included randomised controlled trials (RCTs) for adult patients with IPF receiving one or more of 22 drug treatments. Pairs of reviewers independently identified randomised trials that compared one or more of the target medical treatments in patients with IPF. We assessed the certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach for network meta-analysis. We calculated pooled relative risk (RR) ratios and presented direct or network estimates with 95% credibility intervals (95% CI), within the GRADE framework.Results We identified 48 (10 326 patients) eligible studies for analysis. Nintedanib [RR 0.69 (0.44 to 1.1), pirfenidone [RR 0.63 (0.37 to 1.09); direct estimate), and sildenafil [RR (0.44 (0.16 to 1.09)] probably reduce mortality (all moderate certainty). Nintedanib (2.92% (1.51 to 4.14)), nintedanib+sildenafil (157 mL (–88.35 to 411.12)), pirfenidone (2.47% (–0.1 to 5)), pamrevlumab (4.3% (0.5 to 8.1)) and pentraxin (2.74% (1 to 4.83)) probably reduce decline of overall forced vital capacity (all moderate certainty). Only sildenafil probably reduces acute exacerbation and hospitalisations (moderate certainty). Corticosteroids+azathioprine+N-acetylcysteine increased risk of serious adverse events versus placebo (high certainty).Conclusion and relevance Future guidelines should consider sildenafil for IPF and further research needs to be done on promising IPF treatments such as pamrevlumab and pentraxin as phase 3 trials are completed.Data are available upon reasonable request.